Conditions: Asthma
Keywords: Neutrophilic Asthma
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 19
Healthy volunteers: no

Brief summary:
Evaluation of treatment in participants with mild asthma.

Detailed description:
To evaluate the effect of navarixin (MK-527123, SCH 527123) treatment on allergen-induced late asthmatic response (LAR) in participants with mild asthma.

Arms:
arm 1: Navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 2 arm 2: Matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 2

Interventions: intervention 1: Navarixin intervention 2: Placebo
Intervention descriptions: intervention 1: 30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2 intervention 2: Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2

Protocol document: